Multiple myeloma: therapeutic delivery of antibodies and aptamers

Neret Pujol-Navarro*, Mohammed M. Al Qaraghuli, Karina Kubiak-Ossowska, Manal M. Alsaadi, Gillian A. Horne, Richard L. Soutar, Elpiniki Paspali, Valerie A. Ferro, Mark T.S. Williams, Paul A. Mulheran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.
Original languageEnglish
Pages (from-to)705-722
Number of pages18
JournalTherapeutic Delivery
Volume12
Issue number10
Early online date27 Sep 2021
DOIs
Publication statusPublished - Oct 2021

Keywords

  • antibody-drug conjugates
  • antibody therapy
  • aptamer-drug conjugates
  • aptamer therapy
  • molecular docking
  • multiple myeloma
  • nanoparticles

Fingerprint

Dive into the research topics of 'Multiple myeloma: therapeutic delivery of antibodies and aptamers'. Together they form a unique fingerprint.

Cite this